A

Alexion

Global biopharmaceuticals focusing on rare diseases

Regional Account Manager

Full-TimePosted on 7/27/2026Deadline 10/24/26
No salary listed
Senior
Bachelor's, Master's
Ontario, CA, USA
In PersonTerritory travel is regular and may include frequent overnight and weekend travel.
Sales & Account ManagementField Sales

About the job

Requirements
  • Bachelor’s degree.
  • At least 5 years of experience in specialty pharma, rare disease sales, account management, or complex institutional selling.
  • Strong understanding of healthcare systems, reimbursement processes, fulfillment pathways, and multi-stakeholder decision-making in hospitals, academic centers, integrated delivery networks, and community care settings.
  • Proven track record navigating clinical formulary and access processes, engaging multidisciplinary stakeholders, influencing treatment pathway adoption, and driving utilization within integrated health systems, academic medical centers, and key institutional accounts.
  • Ability to build relationships and influence clinical, administrative, operational, pharmacy, and access stakeholders.
  • Strategic planning, problem-solving, account management, and communication skills.
  • Ability to understand and translate complex clinical data to activate clinical champions and build advocacy within Centers of Excellence, academic centers, hospitals, integrated delivery networks, and other sites of care.
  • Ability to navigate fulfillment, reimbursement, protocol integration, and account-wide operational barriers for assigned diseases.
  • Ability to map complex patient journeys and align account plans to business objectives.
  • Ability to coordinate cross-functional teams and manage role boundaries.
  • Must live in the geographic territory or within 50 miles of the territory border.
  • Ability to travel regularly within the territory, potentially including frequent overnight and weekend travel.
  • Valid driver’s license and clean driving record.
Responsibilities
  • Consistently achieve or exceed sales objectives in the assigned territory and for assigned indications.
  • Develop and execute disease-specific sales account plans for major academic centers, hospitals, integrated delivery networks, community accounts, and other priority sites of care; map stakeholders, patient journeys, diagnostic workflows, referral pathways, and account factors that influence therapy adoption.
  • Identify gaps in diagnostic workflows, referral pathways, operational readiness, clinical protocol adoption, and stakeholder alignment, and implement solutions to optimize appropriate therapy adoption.
  • Drive clinical advocacy and education by building relationships with account stakeholders and developing clinical champions across hematology, hematology/oncology, internal medicine, nephrology, transplant, pharmacy, clinical administration, and other relevant specialties.
  • Deliver approved clinical messaging to influence brand choice, support appropriate formulary access, and educate clinical stakeholders on disease state, unmet needs, diagnostic criteria, and therapy integration.
  • Support account stakeholders’ understanding of operational considerations related to therapy implementation, including treatment workflow, pharmacy, infusion, and other site-of-care processes, and engage appropriate internal partners when broader institutional action is needed.
  • Educate on fulfillment processes, payer access policies, reimbursement frameworks, and common account-wide operational barriers related to prior authorization, access resources, and support.
  • Mobilize cross-functional teams, including SALs, FRMs, PEMs, TLLs, MSLs, Market Access, Diagnostics, and enterprise partners, to deliver account objectives and resolve barriers.
  • Represent customer priorities internally and advocate for solutions addressing account-specific needs while maintaining appropriate role boundaries.
  • Create and maintain account- and indication-specific business plans reflecting local market forces, institution dynamics, care delivery models, access considerations, and multi-stakeholder decision-making.
  • Handle customer questions and objections consistently with product indications and sales training methodology, including compliantly triaging inquiries to the appropriate partner.
  • Use customer relationship management tools to manage territory priorities, track account engagement, document sales activities, submit required reports accurately and on time, and adopt AI-embedded customer relationship management tools to prioritize opportunities and optimize call execution.
  • Use AI-driven insights for territory planning, healthcare professional targeting, and pre-call strategy; translate analytics into focused customer engagement and account action plans.
  • Provide product expertise and customer service across assigned accounts, including complex accounts with multiple stakeholders and sites of care.
  • Perform work in alignment with Alexion’s Code of Ethics and Business Conduct and its policies and procedures.
Desired Qualifications
  • Advanced or master’s degree.
  • Experience selling in orphan or ultra-orphan disease markets.
  • Biopharma experience in hematology, hematology/oncology, oncology, nephrology, transplant, internal medicine, or hospital-based specialty care.
  • Experience working with major academic centers, hospitals, integrated delivery networks, Centers of Excellence, and complex community networks.
  • Demonstrated success driving protocol adoption, formulary support, workflow integration, and multi-stakeholder account pull-through.

About the company

Alexion focuses on discovering, developing, and selling therapies for rare and ultra-rare diseases by targeting the complement system. Its drugs, such as Soliris and Ultomiris, inhibit C5 to block inflammatory cascades, while Strensiq and Kanuma treat metabolic and lysosomal disorders. The company combines in-house R&D with acquisitions to expand its portfolio and leverages AstraZeneca’s global scale to reach patients. Its goal is to improve outcomes for patients with rare diseases and bring these therapies to international markets at premium pricing.

Company Size

5,001-10,000

Company Stage

IPO

Headquarters

Boston, Massachusetts

Founded

1992

Get referred to Alexion

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • AstraZeneca's July 2026 half-year revenue rose 9%, driven partly by Alexion's rare-disease growth.
  • Ultomiris gained FDA Priority Review on June 15, 2026 for IgAN, with Q4 2026 decision.
  • Koselugo's November 2025 adult NF1 approval and ALXN2220 phase 3 expand the pipeline.

What critics are saying

  • EmblemHealth's April 2025 Soliris antitrust suit targets patent settlements and biosimilar delays.
  • Soliris faces biosimilar erosion after March 2025, while Ultomiris still depends on C5-franchise switching.
  • Ultomiris carries meningococcal boxed warnings; a single fatal infection can trigger litigation and prescribing pullback.

What makes Alexion unique

  • Alexion pioneered complement biology, turning C5 inhibition into approved medicines since Soliris, 2007.
  • Ultomiris, Soliris, Strensiq, and Koselugo span hematology, nephrology, endocrinology, and oncology-adjacent rare diseases.
  • AstraZeneca's 2021 acquisition gives Alexion global commercialization scale and deeper trial funding.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Life Insurance
  • Disability Insurance
  • Health Savings Account/Flexible Spending Account
  • Unlimited Paid Time Off
  • Flexible Work Hours
  • Remote Work Options
  • Paid Vacation
  • Paid Sick Leave
  • Paid Holidays

Growth & Insights and Company News

6 month growth

0%

1 year growth

0%

2 year growth

0%
PR Newswire
Aug 23rd, 2024
Global Genes' Annual Week In Rare Event Heading To Kansas City

"Week in RARE provides advocates a unique opportunity to participate in multiple events in one place to maximize their time, travel, and potential to gain benefits from their participation."

StartupTicker
Apr 9th, 2024
Clinical Success For Neurimmune

Schlieren-based startup, Neurimmune, which develops drug candidates for central nervous system (CNS) and related protein aggregation diseases, has, in collaboration with its partner Alexion, advanced its drug candidate ALXN2220 into phase 3. This marks a significant step in the company’s journey to addressing the serious clinical condition ATTR-CM.  Transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) is an underdiagnosed, systemic clinical condition that leads to progressive heart failure and high rate of fatality within four years from diagnosis. Despite recent advances in slowing disease progression, there is currently no treatment available to deplete cardiac ATTR amyloid and revert cardiac dysfunction. Schlieren-based startup, Neurimmune, which develops drug candidates for central nervous system (CNS) and related protein aggregation diseases including Alzheimer’s disease, amyotrophic lateral sclerosis, frontotemporal dementia and ATTR cardiomyopathy, is currently testing a drug candidate, ALXN2220 (formerly NI006), a human antibody targeting ATTR Cardiomyopathy. In 2022, Neurimmune entered into an exclusive global collaboration and license agreement with Alexion, AstraZeneca’s Rare Disease group, for ALXN2220. Neurimmune is responsible for completion of the phase 1b clinical study on behalf of Alexion, with Alexion incurring certain trial costs. Aside from the phase 1b trial, Alexion is responsible for further clinical development, manufacturing, and commercialization as ALXN2220. The two companies have now initiated the phase 3 of the DepleTTR-CM clinical study to assess the efficacy and safety of ALXN2220 for the treatment of ATTR-CM

Business Wire
Apr 1st, 2024
Voydeya™ Approved In The Us As Add-On Therapy To Ravulizumab Or Eculizumab For Treatment Of Extravascular Hemolysis In Adults With The Rare Disease Pnh

WILMINGTON, Del.--(BUSINESS WIRE)--VOYDEYA™ (danicopan) has been approved in the US as add-on therapy to ravulizumab or eculizumab for the treatment of extravascular hemolysis (EVH) in adults with paroxysmal nocturnal hemoglobinuria (PNH).1 VOYDEYA is a first-in-class, oral, Factor D inhibitor developed as an add-on to standard-of-care ULTOMIRIS® (ravulizumab-cwvz) or SOLIRIS® (eculizumab) to address the needs of the approximately 10-20% of patients with PNH who experience clinically significant EVH while treated with a C5 inhibitor.2,3. The approval by the US Food and Drug Administration (FDA) was based on positive results from the pivotal ALPHA Phase III trial. Results from the 12-week primary evaluation period of the trial were published in The Lancet Haematology.2. Bart Scott, MD, Professor, Division of Hematology and Oncology at the University of Washington Medical Center, and Professor, Clinical Research Division at Fred Hutchinson Cancer Center, said: “The approval of VOYDEYA offers this small subset of PNH patients an add-on therapy designed to address EVH, while maintaining disease control with ULTOMIRIS or SOLIRIS. Terminal complement inhibition with ULTOMIRIS can address the life-threatening complications of PNH, building on the efficacy and safety of SOLIRIS established over nearly 20 years.”

Business Wire
Mar 25th, 2024
Ultomiris® (Ravulizumab-Cwvz) Approved In The Us For The Treatment Of Adults With Neuromyelitis Optica Spectrum Disorder (Nmosd)

WILMINGTON, Del.--(BUSINESS WIRE)--ULTOMIRIS® (ravulizumab-cwvz) has been approved in the United States (US) as the first and only long-acting C5 complement inhibitor for the treatment of adult patients with anti-aquaporin-4 (AQP4) antibody-positive (Ab+) neuromyelitis optica spectrum disorder (NMOSD).1. The approval by the US Food and Drug Administration (FDA) was based on positive results from the CHAMPION-NMOSD Phase III trial, which were published in the Annals of Neurology.2 In the trial, ULTOMIRIS was compared to an external placebo arm from the pivotal SOLIRIS® PREVENT clinical trial. ULTOMIRIS met the primary endpoint of time to first on-trial relapse as confirmed by an independent adjudication committee. Zero relapses were observed among ULTOMIRIS patients with a median treatment duration of 73 weeks (relapse risk reduction: 98.6%, hazard ratio (95% CI): 0.014 (0.000, 0.103), p0.0001).2

PharmiWeb
Nov 28th, 2023
Nice Endorses Only Approved Treatment For Ultra-Rare Wolman Disease For Children Diagnosed Under The Age Of Two: Interview Opportunity

Sebelipase alfa (Kanuma®▼) recommended by NICE as the first treatment for infants with ultra-rare Wolman Disease.  . Kanuma, an enzyme replacement therapy, is the first medicine to be recommended for this life-threatening condition in infants under two years old

INACTIVE